Hologic, Inc.’s Stock Price Drops to $54.16, Experiencing a Sharp Decrease of 5.45%

Hologic, Inc. (HOLX)

54.16 USD -3.12 (-5.45%) Volume: 7.84M

Hologic, Inc.’s stock price currently stands at 54.16 USD, experiencing a downturn this trading session with a percentage change of -5.45%. With a trading volume of 7.84M, the stock has seen a substantial year-to-date (YTD) decline of -24.87%, making it a significant point of focus for investors tracking HOLX’s performance.

Latest developments on Hologic, Inc.

Amid a series of challenges and strategic growth initiatives, Hologic Inc. (HOLX) saw its stock underperform on Friday in comparison to its competitors. The company’s Q2 2025 earnings call highlighted the efforts being made to navigate these challenges while focusing on growth. Despite exceeding revenue guidance, the ’25 EPS view was lowered, leading to a decrease in stock value. Analysts adjusted price targets, with Leerink Partners lowering it to $60 from $65, and RBC Capital also reducing their target. Hologic’s stock price took a hit after receiving a hold rating from Needham Analyst and facing tariff pressures and geopolitical uncertainties, resulting in a revised earnings outlook. The company’s Q2 earnings report showcased revenue hitting $1,005.3M, with non-GAAP EPS at $1.03, surpassing estimates. Looking ahead, Hologic outlined a Q3 2025 revenue target of $1B-$1.01B as part of its breast health recovery strategy.

Hologic, Inc. on Smartkarma

Analysts from Baptista Research have provided bullish coverage on Hologic Inc on Smartkarma, highlighting the company’s expansion in diagnostic assay portfolio for a competitive edge. In their report titled “Hologic Inc.: Expanding Diagnostic Assay Portfolio For A Competitive Edge! – Major Drivers”, they discussed the company’s financial results for the fourth quarter and fiscal year 2024. The total revenue in the fourth quarter was $987.9 million, with a 4.2% increase compared to the previous year. Non GAAP earnings per share (EPS) also grew by 13.5% to $1.01, showing both strengths and challenges for the company.

Furthermore, in another report titled “Hologic: The Future of 3D Mammography and Molecular Diagnostics—What’s Next?”, Baptista Research discussed Hologic Inc‘s first-quarter fiscal 2025 results. Despite facing challenges impacting revenue streams, the company reported an overall revenue of $1.022 billion, marking a modest 1% increase on a constant currency basis. The impact of the stronger U.S. dollar reduced reported revenue by about $9 million, showing the analysts’ bullish sentiment towards the company’s future prospects.

A look at Hologic, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on Smartkarma Smart Scores, Hologic Inc has a mixed outlook for the long term. While the company scores well in terms of Momentum, indicating strong performance trends, it falls short in the Dividend and Growth categories. This suggests that Hologic Inc may not be the best choice for investors seeking steady income or significant growth potential.

However, with solid scores in Value and Resilience, Hologic Inc shows promise in terms of being a stable and reliable investment option. The company’s focus on diagnostics, breast health, GYN surgical, and skeletal health products also positions it well in the healthcare industry. Overall, investors may want to consider Hologic Inc for its strong momentum and resilience, despite lower scores in other key areas.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma